SCHEMBL15467910

SCHEMBL15467910

NC1(c2ccc(OC(F)(F)F)cc2)CCOc2cccnc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.49
NR1I2 O75469 1/20 0.38
SCN9A Q15858 2/20 0.37
SCN10A Q9Y5Y9 2/20 0.37
SCN1A P35498 1/20 0.37
SCN4A P35499 1/20 0.37
KCNH2 Q12809 1/20 0.37
SCN5A Q14524 1/20 0.37
SCN2A Q99250 1/20 0.37
SCN3A Q9NY46 1/20 0.37
SCN8A Q9UQD0 1/20 0.37
SLC6A4 P31645 3/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
PRCP P42785 4/20 0.36
CTSD P07339 2/20 0.35
BACE1 P56817 2/20 0.35
BACE2 Q9Y5Z0 2/20 0.35
REN P00797 1/20 0.35
HCRTR1 O43613 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16421213 1.00 TRPM8 (0.49) TRPM8NR1I2SCN9ASCN10ASCN1A
Hydrochloric Acid SCHEMBL15567851 0.99 TRPM8 (0.49) TRPM8NR1I2SCN9ASCN10ASCN1A
Hydrochloric Acid SCHEMBL15567852 0.99 TRPM8 (0.49) TRPM8NR1I2SCN9ASCN10ASCN1A
SCHEMBL15473313 0.84 TRPM8 (0.41) TRPM8PDE2A
SCHEMBL15473295 0.84 TRPM8 (0.41) TRPM8PDE2A
SCHEMBL16421219 0.84 TRPM8 (0.41) TRPM8KCNH2SCN5APDE2AHSD11B1
SCHEMBL15467712 0.84 TRPM8 (0.35) TRPM8SLC6A3BACE1
SCHEMBL15467859 0.84 TRPM8 (0.35) TRPM8SLC6A3BACE1
SCHEMBL15467465 0.83 TRPM8 (0.51) TRPM8NR1I2SCN9ASCN10ASCN1A
SCHEMBL15468093 0.83 TRPM8 (0.44) TRPM8SCN9ASCN10ASCN1ASCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885NR1I2 943/4885SCN9A 66/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885NR1I2 943/4885SCN9A 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.